LENZ Therapeutics Files 8-K: Material Agreement & Exhibits

Ticker: LENZ · Form: 8-K · Filed: Apr 4, 2025 · CIK: 1815776

Lenz Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLenz Therapeutics, Inc. (LENZ)
Form Type8-K
Filed DateApr 4, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, filing, corporate-actions

TL;DR

LENZ Therapeutics filed an 8-K today, looks like a big deal is happening.

AI Summary

On April 4, 2025, LENZ Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, previously known as Graphite Bio, Inc. and Integral Medicines, Inc., is incorporated in Delaware and headquartered in Solana Beach, California.

Why It Matters

This 8-K filing signals a significant development for LENZ Therapeutics, potentially related to a new partnership, acquisition, or financing, which could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — 8-K filings often disclose material events that can significantly impact a company's stock price, requiring careful investor attention.

Key Numbers

  • 001-40532 — SEC File Number (Identifies the company's filing with the SEC.)
  • 844867570 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • LENZ Therapeutics, Inc. (company) — Registrant
  • Graphite Bio, Inc. (company) — Former company name
  • Integral Medicines, Inc. (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • Solana Beach, California (location) — Principal executive offices location
  • April 4, 2025 (date) — Date of report

FAQ

What is the nature of the material definitive agreement entered into by LENZ Therapeutics?

The filing does not specify the details of the material definitive agreement, only that one has been entered into.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on April 4, 2025.

What were LENZ Therapeutics' former company names?

LENZ Therapeutics was formerly known as Graphite Bio, Inc. and Integral Medicines, Inc.

Where are LENZ Therapeutics' principal executive offices located?

LENZ Therapeutics' principal executive offices are located at 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, California 92075.

What is the SIC code for LENZ Therapeutics?

The Standard Industrial Classification (SIC) code for LENZ Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 4, 2025 regarding LENZ Therapeutics, Inc. (LENZ).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.